Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516489 | 0.84 | CREBBP (0.44) | MAPTCREBBPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL22424939 | 0.81 | MEN1 (0.60) | MAPTCREBBPTSHRMEN1KMT2A | |
| SCHEMBL12232438 | 0.80 | CREBBP (0.50) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4576717 | 0.80 | GRIN2D (0.55) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21460047 | 0.80 | NOS1 (0.56) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31129257 | 0.79 | CREBBP (0.61) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9678808 | 0.78 | CREBBP (0.56) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22425024 | 0.76 | NOS1 (0.60) | MAPTCREBBPNOS1MAPKAPK2 | |
| SCHEMBL4577561 | 0.76 | MAPT (0.56) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24430175 | 0.76 | CREBBP (0.52) | CREBBPGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | MAPT 3836/4885CREBBP 3896/4885GRIN2D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.